A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2004
11/11/2004	US20040224985 for controlling weight; pyrrolidine or piperidine compounds
11/11/2004	US20040224984 Treatment of skin disorders and antiinflammatory agents, fungicides or bactericides
11/11/2004	US20040224983 Cholecystokinin receptors as modulators to mediate diseases and gastrointestinal disorders
11/11/2004	US20040224980 Compounds used as drugs in solvents as analgesics
11/11/2004	US20040224979 Treating obesity with selective androgen receptor modulators
11/11/2004	US20040224978 CCR8 inhibitors
11/11/2004	US20040224977 Racemic mixtures for treatment of diseases with alpha 7nicotinic acetyl chloline administering
11/11/2004	US20040224976 Azabicyclic compounds for the treatment of disease
11/11/2004	US20040224975 Nicotinamide derivatives useful as PDE4 inhibitors
11/11/2004	US20040224970 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
11/11/2004	US20040224969 Salts of substituted 1,2,3,4-tetrahydroquinoline-2-carboxylic acid compounds
11/11/2004	US20040224966 Enzyme inhibitors as drugs for cardiovascular disorders, aids, alzheimers disease or urogenital disorders
11/11/2004	US20040224965 Treatment of cardiovascular disorders, thrombosis, surgery and nhe inhibitors
11/11/2004	US20040224962 Treatment of obesity with drugs and to promote weight loss using nicotinic receptors
11/11/2004	US20040224961 Novel thiazolo (4,5-D) pyrimidine compounds
11/11/2004	US20040224960 Pharmaceutical compositions and methods for their use
11/11/2004	US20040224958 Pyridopyrimidinone derivatives for treatment of neurodegenerative disease
11/11/2004	US20040224957 Melanocortin receptor-specific compounds
11/11/2004	US20040224956 Crystal of 6-[4-(4-pyridylamino)phenyl]-4,5-dihydro-3(2h)-pyridazinone hydrochloride trihydrate
11/11/2004	US20040224955 Viral polymerase inhibitors
11/11/2004	US20040224954 Substituted 1H-quinoxalin-2-one compounds and substituted 4-aryl- and 4-heteroarylcyclohexane compounds
11/11/2004	US20040224950 e.g., N-Cycloheptyl-N'(1-ethyl-pyrrolidin-2-ylmethyl)-6-(3-fluoro-4-methoxy-phenoxy)-[1,3,5]triazine-2,4-diamine; treating unwanted cellular proliferation, an inflammation mediated disease, or a hyperproliferative disease, or modulating a glycosidase enzyme
11/11/2004	US20040224949 Modified release formulations of at least one form of tramadol
11/11/2004	US20040224948 Novel substituted benzoxazines as integrin antagonists
11/11/2004	US20040224947 Non-sedating barbiturate compounds as neuroprotective agents
11/11/2004	US20040224945 Novel substituted pyrazole derivatives
11/11/2004	US20040224943 Administering to the individual an effective amount of (S)-tofisopam, substantially isolated from the corresponding (R)-enantiomer of tofisopam, or a pharmaceutically-acceptable salt thereof
11/11/2004	US20040224942 Use of N-desmethylclozapine to treat human neuropsychiatric disease
11/11/2004	US20040224941 Carboxylic acid derivatives and drugs containing the same as the active ingredient
11/11/2004	US20040224940 Diagnosing a subject in need of treatment for a stroke; administering to the subject a cyclooxygenase-2 selective inhibitor or an isomer, a pharmaceutically acceptable salt, ester, or prodrug thereof and a sodium ion channel blocker
11/11/2004	US20040224939 Antibacterial agents
11/11/2004	US20040224938 Substituted benzo [b] azepin-2-one compounds
11/11/2004	US20040224937 Administering to the patient a therapeutically effective amount of a protein kinase C (PKC) inhibitor
11/11/2004	US20040224936 Macrocyclic compounds useful as pharmaceuticals
11/11/2004	US20040224935 Topical antiandrogenic steroids
11/11/2004	US20040224934 3 -oxo-androstrane carbothioic acid compound
11/11/2004	US20040224933 Reducing compound such as 3,3-ethylenedioxyestra-5(10), 9(11)-dien-17-ol, halogenating, epoxidation, alkylation, deprotecting, aromatization, saponification, neutralization to obtain compound such as 11-beta-(4-(2-(1-piperidinyl)ethoxy)phenyl)-17-alpha-fluoroestra-1,3,5(10)-trien-3-ol
11/11/2004	US20040224932 crystal structure; antiinflammatory agents; antiallergens
11/11/2004	US20040224931 3-oxo-androstrane carbothioic acid compound
11/11/2004	US20040224930 25-SO2-Substituted analogs of 1mu,25-dihydroxyvitamin D3
11/11/2004	US20040224929 Novel vitamin D analogs
11/11/2004	US20040224928 For therapy of bacterial infections and neoplasms,
11/11/2004	US20040224926 Inhibitory or blocking agents of molecular generating and/or inducing functions
11/11/2004	US20040224925 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs
11/11/2004	US20040224924 Programming a specific course and rate for a parent drug compound's metabolism that leads to an inactive or weakly active and non-toxic metabolite when the parent drug compound is administered, comprising modifying the parent drug compound by forming one or more of a predetermined chemical arrangement
11/11/2004	US20040224923 For therapy of bacterial and/or fungal infections
11/11/2004	US20040224922 Administering to the respiratory tract mucus of an animal need thereof that does not have a known respiratory tract bacterial infection, an effective amount of charged dextran for decreasing viscoelasticity of respiratory tract mucus
11/11/2004	US20040224919 Restoring cancer-suppressing functions to neoplastic cells through DNA hypomethylation
11/11/2004	US20040224918 Inhibiting, reversing or eliminating an infection of a eukaryotic cell by a mycobacterium by contacting the cell with an antimycobacterial compound such as isoniazid-NADH that is an inhibitor of a mycobacterium-specific enzyme
11/11/2004	US20040224917 Administering combination of [2-(6-amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid diisopropoxycarbonyloxymethyl ester fumarate (tenofovir disoproxil fumarate) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine)
11/11/2004	US20040224916 Administering combination comprising 9-[R-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine (GS-7340) or a physiologically functional derivative thereof, and (2R,5S,cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine)
11/11/2004	US20040224908 for treating Gram-positive bacterial infection of skin and soft tissue; remains at therapeutic levels in the bloodstream for 7 days or longer
11/11/2004	US20040224907 Compositions and methods for reversal of drug resistance
11/11/2004	US20040224905 Applying to an area in need thereof, an effective amount of a one or more rhamnolipids for therapy of gingivitis
11/11/2004	US20040224904 Carbohydrate scaffold, carrying two side chains, which form a macrocyclic ring that may be unsaturated and contains ether, amide, ester and/or carbamate groups; for therapy of bacterial, fungal, viral or protozoal infections or tumors
11/11/2004	US20040224902 Process for obtaining lignans
11/11/2004	US20040224901 for example, (3R)-N-[(1R)-1-[(4-Chlorophenyl)methyl]-2-[3-[cyclohexyl(5-isoxazolylcarbonyl)amino]-1-pyrrolidinyl]-2-oxoethyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide; for treating conditions responsive to the modulation of melanocortin-4 receptors such as obesity, diabetes, and sexual dysfunction
11/11/2004	US20040224899 Use of s-nitrosothiol signaling to treat disordered control of breathing
11/11/2004	US20040224893 administering interleukin-1 antagonists; restenosis, atherosclerosis, vascular access dysfunction; anticholesterol, hypotensive agents
11/11/2004	US20040224892 Oligosaccharides in cosmetic or dermatological compositions for stimulating adhesion of keratinocytes to major proteins of the dermoepidermal junction and restoration of epidermal cohesion
11/11/2004	US20040224884 drug screening; increasing bone mass without compromising bone strength or quality by administering an apototic or antiapoptotic agent that binds to the estrogen or androgen receptor without causing hormonal transcriptional activation; bone disorders
11/11/2004	US20040224880 Regulation of gastric acid secretion by inwardly rectifying k+ channels
11/11/2004	US20040224878 Fertilization of aged oocytes
11/11/2004	US20040224877 drug delivery method of deglycosylated Vitamin D binding protein (DBP-maf) for angiogenesis inhibition; anticarcinogenic, antitumor agents
11/11/2004	US20040224876 Combination therapy for the treatment of immunoinflammatory disorders
11/11/2004	US20040224875 Inhibitors of glutaminyl cyclase
11/11/2004	US20040224360 Methods for diagnosing renal disorders
11/11/2004	US20040224355 Using guanylate cyclase gene expression for imaging and treating primary and/or metastatic stomach or esophageal cancer; tissue targeted therapy; genetic vaccines; immunotherapy
11/11/2004	US20040224316 Using phosphodiesterase 4 inhibitor to treat cognitive training disorders; learning enhancement and enzyme inhibitors
11/11/2004	US20040224314 G-protein coupled receptors
11/11/2004	US20040224313 Comprises nucleotide sequences coding cytochrome p450 oxygenase variant for identifying modulator use in diagnosis, prognosis, treatment and prevention of cell proliferative disorders; antitumor agents
11/11/2004	US20040224073 Soluble roasted chicory having high inulin content
11/11/2004	US20040224060 A homogeneous extruded product comprising decorticated Milo seeds and fungicides, selected from a solid chlorine mixture, sodium nitrate, and garlic extract; use in building industry, construction materials, basements, prevent mold growth
11/11/2004	US20040224039 Compositions and methods for the treatment of diseases and disorder associated with oxidative damage
11/11/2004	US20040224038 Selectively inhibiting estrogen production and providing estrogenic effects in the human body
11/11/2004	US20040224037 use of Capsaicin, vanilloids and capsicum extract, intravenous and by subcutaneous or intramuscular administration at low concentration implemented by using infuses inhibits virus replication, control oportunistic illnesses, and minimize a Bezold-Jarisch reflex by reducing a side effect
11/11/2004	US20040224036 Dietary supplement and method for the treatment and prevention of digestive tract ulcers in equines and other animals
11/11/2004	US20040224035 Dietary supplements containing extracts of cinnamon and methods of using same to enhance creatine transport
11/11/2004	US20040224034 treating a disease or a condition in a mammal by modulating Cox-2 gene expression by administering black tea extract which comprises theaflavin-3-gallate and theaflavin-3'-gallate mixture; for therapy and prophylaxis of cancer, inflammation, and arthritis
11/11/2004	US20040224033 Side effect-relieving agents and/or hypoglycemic effect enhancers for thiazolidine compounds
11/11/2004	US20040224031 synergistic insulin mimikers with lower toxicity since less vanadium compound needed; amine is semicarbazide-sensitive amine oxidase (SSAO) substrate; benzylamine and tyramine with sodium orthovanadate
11/11/2004	US20040224023 Compositions and methods for treating or preventing diseases of body passageways
11/11/2004	US20040224020 selectively enhancing analgesic potency of an opioid agonist or attenuating an adverse side effect of the opioid agonist; e.g. controlled release core comprises oxycodone, and the immediate release gelatin capsule comprises oxycodone and an opioid antagonist such as naltrexone
11/11/2004	US20040224014 particularly norfloxacin, containing an inorganic or organic acid stabilizer; for preparing a tablet by wet granulation
11/11/2004	US20040224006 defibrinogenating agent, e.g., ancrod, urokinase, streptokinase, phenobarbital or valproic acid; or a fibrinolytic agent, e.g., advance-generation fibrates, e.g., fenofibrate, a tissue-plasminogen activator that may be recombinant, or a fibrinolytic derivative of recombinant tissue-plasminogen activator
11/11/2004	US20040224004 Methods and products for bad breath
11/11/2004	US20040224003 Drug formulations for coating medical devices
11/11/2004	US20040223999 Mold inhibitor integrated within a matrix and method of making same
11/11/2004	US20040223984 Topical testosterone formulations and associated methods
11/11/2004	US20040223971 augmenting treatment of cancers and other proliferative disorders by administering an agent that inhibits the antiapoptotic activity of galectin-3 in combination with a chemotherapeutic agent whose cytotoxicity is influenced by the status of an anti-apoptotic Bcl-2 protein to potentiate its activity
11/11/2004	US20040223964 Secreted and transmembrane polypeptides and nucleic acids encoding the same
11/11/2004	US20040223963 Method for treating ischemic stroke with melatonin
11/11/2004	US20040223958 Glutathione reductase for therapy and prophylaxis of AIDS
11/11/2004	US20040223946 applying an adhesive composition comprising a polymerizable alpha -cyanoacrylate monomer optionally with an additional active agent such as an antipruitic agent to the insect bite; and allowing the monomer to polymerize to form a film over said area of skin with the bite.
11/11/2004	US20040223932 applying an adhesive composition comprising a polymerizable monomer to an area of skin that is afflicted with acne; and allowing the monomer to polymerize to form a polymer film over said area of skin.
11/11/2004	US20040223922 Clear micellized formulations of beta-carotene and method of treating leukoplakia
11/11/2004	US20040223920 Treating disease of the airway passages and lungs such as asthma and allergic rhinitis by administering intranasally or oral inhalation; low bioavailability and low systemic side-effects; aerosols
11/11/2004	US20040223918 includes ethanol as a high volatility carrier and an optional additive such as a surfactant and/or low volatility liquid; propellant-free
11/11/2004	US20040223916 for a metered dose inhaler having part or all of its internal surfaces coated with one or more fluorocarbon polymers, optionally in combination with one or more non-fluorocarbon polymers and having a wall with a thickness of 0.55 mm to 1.00 mm
11/11/2004	US20040223913 benz[e]indole derivatives that absorb and fluoresce in the visible region of light, particularly useful for optical diagnosis of renal and cardiac diseases and for estimation of blood volume in vivo.

1 ... 4895 4896 4897 4898 4899 4900 4901 4902 4903 4904 4905 4906 4907 4908 4909 4910 4911 4912 4913 4914 4915 ... 7860